NCT03751735

Efficacy of Wharton Jelly in Erectile Dysfunction

Evaluation of the Efficacy for Two Doses of Intracavernous Injection of Wharton Jelly Stem Cells for the Treatment of Diabetic Erectile Dysfunction

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Sophia Al-Adwan · Academic / Other
• Sex: Male
• Age: 25 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Efficacy of Intracavernous injection of Wharton jelly Mesenchymal stem cells for the treatment of erectile dysfunction in diabetic patients.

Detailed description

This study will be conducted at the Cell Therapy Center (CTC), Jordan, in which 22 male patients ranging from 25-70 years diagnosed with erectile dysfunction will be selected. This diagnosis is based on medical history, validated questionnaires, physical examinations, laboratory tests and specific diagnostic tests. The patients are followed by clinical assessment, laboratory investigations as well as Doppler ultrasound. The investigators hypothesize that the intracavernous injection of stem cells will facilitate the recovery of erectile function resulting in satisfying clinical outcomes in patients.

Conditions

• Erectile Dysfunction Associated With Type 2 Diabetes Mellitus

Interventions

Type	Name	Description
BIOLOGICAL	Wharton Jelly Mesenchymal stem cells	Intracavernous injection of Wharton Jelly Mesenchymal stem cells.

Timeline

• Start date: 2017-01-27
• Primary completion: 2019-01-13
• Completion: 2019-02-26
• First posted: 2018-11-23
• Last updated: 2019-04-10

Locations

1 site across 1 country: Jordan